

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

EPAS ID: PAT3602201

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
SANG PHIL YOON	08/13/2015
KI SEONG KO	08/13/2015
HA NA YU	08/13/2015
HYE JUNG BAIK	08/13/2015
WON KYU YANG	08/13/2015
JIN YOUNG KO	08/13/2015
SO HYUN PARK	08/13/2015
SUNG BUM JUNG	08/13/2015
SUNG WON AN	08/13/2015
MIN HYO KI	08/13/2015
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	CHONG KUN DANG PHARMACEUTICAL CORP.
<b>Street Address:</b>	8, CHUNGJEONG-RO, SEODAEMUN-GU
<b>City:</b>	SEOUL
<b>State/Country:</b>	KOREA, REPUBLIC OF
<b>Postal Code:</b>	120-756
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
Application Number:	14440060
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(619)595-8135
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	619-595-8010
<b>Email:</b>	MLAIPSD@DENTONS.COM
<b>Correspondent Name:</b>	STEPHANIE L. SEIDMAN
<b>Address Line 1:</b>	DENTONS US LLP
<b>Address Line 2:</b>	4435 EASTGATE MALL, SUITE 400
<b>Address Line 4:</b>	SAN DIEGO, CALIFORNIA 92121
<b>ATTORNEY DOCKET NUMBER:</b>	34105.00441.US00/441US

PATENT

<b>NAME OF SUBMITTER:</b>	STEPHANIE SEIDMAN
<b>SIGNATURE:</b>	/Stephanie Seidman/
<b>DATE SIGNED:</b>	11/04/2015
<b>Total Attachments: 20</b> source=441US - Executed Assignments#page1.tif source=441US - Executed Assignments#page2.tif source=441US - Executed Assignments#page3.tif source=441US - Executed Assignments#page4.tif source=441US - Executed Assignments#page5.tif source=441US - Executed Assignments#page6.tif source=441US - Executed Assignments#page7.tif source=441US - Executed Assignments#page8.tif source=441US - Executed Assignments#page9.tif source=441US - Executed Assignments#page10.tif source=441US - Executed Assignments#page11.tif source=441US - Executed Assignments#page12.tif source=441US - Executed Assignments#page13.tif source=441US - Executed Assignments#page14.tif source=441US - Executed Assignments#page15.tif source=441US - Executed Assignments#page16.tif source=441US - Executed Assignments#page17.tif source=441US - Executed Assignments#page18.tif source=441US - Executed Assignments#page19.tif source=441US - Executed Assignments#page20.tif	

ASSIGNMENT

I, Sang Phil YOON (hereinafter Assignor), a citizen of the Republic of Korea, having a mailing address of 315-20, Dongbaekjukjeon-daero, Giheung-gu, Yongin-si, Gyeonggi-do 446-916, Republic of Korea, for good and valuable consideration, have assigned and do hereby assign to CHONG KUN DANG PHARMACEUTICAL CORP. (hereinafter Assignee), a corporation organized under the laws of the Republic of Korea, having a principal business address of 8, Chungjeong-ro, Seodaemun-gu, Seoul 120-756, Republic of Korea, its successors, assigns and legal representatives, the entire right, title and interest in and to the subject matter disclosed in U.S. National Phase Patent Application Serial No. 14/440,060 entitled:

SUSTAINED-RELEASE LIPID PRE-CONCENTRATE OF GNRH  
ANALOGUES AND PHARMACEUTICAL COMPOSITION  
COMPRISING THE SAME

which was filed on April 30, 2015, and in and to all Convention and Treaty rights of all kinds, in all countries throughout the world, for all such subject matter, including the right to claim for any such applications any priority rights to which such applications are entitled under international conventions, treaties or otherwise and, in and to, all Letters Patent to be obtained for said subject matter by the above application or any continuation, division, continuation-in-part, extension, conversion to 35 USC 111(b) or substitute thereof, and any reissue, reexamination or extension of said Letters Patent.

ASSIGNMENT  
Sang Phil YOON *et al.*

I agree to do all acts and sign all documents necessary to secure, defend and maintain all said Letters Patent and rights, including any continuations, divisionals, reissues, renewals and extensions, and request issuance of all said Letters Patent to the above Assignee in accordance with this assignment.

ASSIGNOR:

DATE: 2015. 8. 13



\_\_\_\_\_  
Sang Phil YOON

WITNESSED:

DATE: August 13, 2015




\_\_\_\_\_  
[SIGNATURE OF WITNESS]

Ye Jin KWON

\_\_\_\_\_  
[PRINTED NAME OF WITNESS]

WITNESSED:

DATE: August 13, 2015



\_\_\_\_\_  
[SIGNATURE OF WITNESS]

Jae Ock CHO

\_\_\_\_\_  
[PRINTED NAME OF WITNESS]

ASSIGNMENT

I, **Ki Seong KO** (hereinafter **Assignor**), a citizen of the Republic of Korea, having a mailing address of 315-20, Dongbaekjukjeon-daero, Giheung-gu, Yongin-si, Gyeonggi-do 446-916, Republic of Korea, for good and valuable consideration, have assigned and do hereby assign to **CHONG KUN DANG PHARMACEUTICAL CORP.** (hereinafter **Assignee**), a corporation organized under the laws of the Republic of Korea, having a principal business address of 8, Chungjeong-ro, Seodaemun-gu, Seoul 120-756, Republic of Korea, its successors, assigns and legal representatives, the entire right, title and interest in and to the subject matter disclosed in U.S. National Phase Patent Application Serial No. 14/440,060 entitled:

**SUSTAINED-RELEASE LIPID PRE-CONCENTRATE OF GNRH  
ANALOGUES AND PHARMACEUTICAL COMPOSITION  
COMPRISING THE SAME**

which was filed on April 30, 2015, and in and to all Convention and Treaty rights of all kinds, in all countries throughout the world, for all such subject matter, including the right to claim for any such applications any priority rights to which such applications are entitled under international conventions, treaties or otherwise and, in and to, all Letters Patent to be obtained for said subject matter by the above application or any continuation, division, continuation-in-part, extension, conversion to 35 USC 111(b) or substitute thereof, and any reissue, reexamination or extension of said Letters Patent.

ASSIGNMENT  
Sang Phil YOON *et al.*

I agree to do all acts and sign all documents necessary to secure, defend and maintain all said Letters Patent and rights, including any continuations, divisionals, reissues, renewals and extensions, and request issuance of all said Letters Patent to the above Assignee in accordance with this assignment.

ASSIGNOR:

DATE: 2015-8-13



\_\_\_\_\_  
Ki Seong KO

WITNESSED:

DATE: August 13, 2015




\_\_\_\_\_  
[SIGNATURE OF WITNESS]

Ye Jin KWON

\_\_\_\_\_  
[PRINTED NAME OF WITNESS]

WITNESSED:

DATE: August 13, 2015



\_\_\_\_\_  
[SIGNATURE OF WITNESS]

Jae Ock CHO

\_\_\_\_\_  
[PRINTED NAME OF WITNESS]

ASSIGNMENT

I, Ha Na YU (hereinafter Assignor), a citizen of the Republic of Korea, having a mailing address of 315-20, Dongbaekjukjeon-daero, Giheung-gu, Yongin-si, Gyeonggi-do 446-916, Republic of Korea, for good and valuable consideration, have assigned and do hereby assign to CHONG KUN DANG PHARMACEUTICAL CORP. (hereinafter Assignee), a corporation organized under the laws of the Republic of Korea, having a principal business address of 8, Chungjeong-ro, Seodacmun-gu, Seoul 120-756, Republic of Korea, its successors, assigns and legal representatives, the entire right, title and interest in and to the subject matter disclosed in U.S. National Phase Patent Application Serial No. 14/440,060 entitled:

SUSTAINED-RELEASE LIPID PRE-CONCENTRATE OF GNRH  
ANALOGUES AND PHARMACEUTICAL COMPOSITION  
COMPRISING THE SAME


which was filed on April 30, 2015, and in and to all Convention and Treaty rights of all kinds, in all countries throughout the world, for all such subject matter, including the right to claim for any such applications any priority rights to which such applications are entitled under international conventions, treaties or otherwise and, in and to, all Letters Patent to be obtained for said subject matter by the above application or any continuation, division, continuation-in-part, extension, conversion to 35 USC 111(b) or substitute thereof, and any reissue, reexamination or extension of said Letters Patent.

ASSIGNMENT  
Sang Phil YOON *et al.*

I agree to do all acts and sign all documents necessary to secure, defend and maintain all said Letters Patent and rights, including any continuations, divisionals, reissues, renewals and extensions, and request issuance of all said Letters Patent to the above Assignee in accordance with this assignment.


ASSIGNOR:

DATE: 2015. 8. 13

  
\_\_\_\_\_  
Ha Na YU

WITNESSED:


DATE: August 13, 2015

  
\_\_\_\_\_  
[SIGNATURE OF WITNESS]

Ye Jin KWON  
\_\_\_\_\_  
[PRINTED NAME OF WITNESS]

WITNESSED:

DATE: August 13, 2015

  
\_\_\_\_\_  
[SIGNATURE OF WITNESS]

Jae Ock CHO  
\_\_\_\_\_  
[PRINTED NAME OF WITNESS]



ASSIGNMENT

I, Hye Jung BAIK (hereinafter Assignor), a citizen of the Republic of Korea, having a mailing address of 315-20, Dongbaekjukjeon-daero, Giheung-gu, Yongin-si, Gyeonggi-do 446-916, Republic of Korea, for good and valuable consideration, have assigned and do hereby assign to CHONG KUN DANG PHARMACEUTICAL CORP. (hereinafter Assignee), a corporation organized under the laws of the Republic of Korea, having a principal business address of 8, Chungjeong-ro, Seodaemun-gu, Seoul 120-756, Republic of Korea, its successors, assigns and legal representatives, the entire right, title and interest in and to the subject matter disclosed in U.S. National Phase Patent Application Serial No. 14/440,060 entitled:

SUSTAINED-RELEASE LIPID PRE-CONCENTRATE OF GNRH  
ANALOGUES AND PHARMACEUTICAL COMPOSITION  
COMPRISING THE SAME

which was filed on April 30, 2015, and in and to all Convention and Treaty rights of all kinds, in all countries throughout the world, for all such subject matter, including the right to claim for any such applications any priority rights to which such applications are entitled under international conventions, treaties or otherwise and, in and to, all Letters Patent to be obtained for said subject matter by the above application or any continuation, division, continuation-in-part, extension, conversion to 35 USC 111(b) or substitute thereof, and any reissue, reexamination or extension of said Letters Patent.

ASSIGNMENT  
Sang Phil YOON *et al.*

I agree to do all acts and sign all documents necessary to secure, defend and maintain all said Letters Patent and rights, including any continuations, divisionals, reissues, renewals and extensions, and request issuance of all said Letters Patent to the above Assignee in accordance with this assignment.


ASSIGNOR:

DATE: 2015. 8. 13

  
\_\_\_\_\_  
Hye Jung BAIK

WITNESSED:


DATE: August 13, 2015

  
\_\_\_\_\_  
[SIGNATURE OF WITNESS]

Ye Jin KWON  
\_\_\_\_\_  
[PRINTED NAME OF WITNESS]

WITNESSED:

DATE: August 13, 2015

  
\_\_\_\_\_  
[SIGNATURE OF WITNESS]

Jae Ock CHO  
\_\_\_\_\_  
[PRINTED NAME OF WITNESS]

ASSIGNMENT

I, **Won Kyu YANG** (hereinafter Assignor), a citizen of the Republic of Korea, having a mailing address of 315-20, Dongbaekjukjeon-daero, Giheung-gu, Yongin-si, Gyeonggi-do 446-916, Republic of Korea, for good and valuable consideration, have assigned and do hereby assign to **CHONG KUN DANG PHARMACEUTICAL CORP.** (hereinafter Assignee), a corporation organized under the laws of the Republic of Korea, having a principal business address of 8, Chungjeong-ro, Seodaemun-gu, Seoul 120-756, Republic of Korea, its successors, assigns and legal representatives, the entire right, title and interest in and to the subject matter disclosed in U.S. National Phase Patent Application Serial No. 14/440,060 entitled:

**SUSTAINED-RELEASE LIPID PRE-CONCENTRATE OF GNRH  
ANALOGUES AND PHARMACEUTICAL COMPOSITION  
COMPRISING THE SAME**

which was filed on April 30, 2015, and in and to all Convention and Treaty rights of all kinds, in all countries throughout the world, for all such subject matter, including the right to claim for any such applications any priority rights to which such applications are entitled under international conventions, treaties or otherwise and, in and to, all Letters Patent to be obtained for said subject matter by the above application or any continuation, division, continuation-in-part, extension, conversion to 35 USC 111(b) or substitute thereof, and any reissue, reexamination or extension of said Letters Patent.

ASSIGNMENT  
Sang Phil YOON *et al.*

I agree to do all acts and sign all documents necessary to secure, defend and maintain all said Letters Patent and rights, including any continuations, divisionals, reissues, renewals and extensions, and request issuance of all said Letters Patent to the above Assignee in accordance with this assignment.

ASSIGNOR:

DATE: 2015 08 13



\_\_\_\_\_  
Won Kyu YANG

WITNESSED:

DATE: August 13, 2015




\_\_\_\_\_  
[SIGNATURE OF WITNESS]

Ye Jin KWON

\_\_\_\_\_  
[PRINTED NAME OF WITNESS]

WITNESSED:

DATE: August 13, 2015



\_\_\_\_\_  
[SIGNATURE OF WITNESS]

Jae Ock CHO

\_\_\_\_\_  
[PRINTED NAME OF WITNESS]

ASSIGNMENT

I, Jin Young KO (hereinafter Assignor), a citizen of the Republic of Korea, having a mailing address of 315-20, Dongbaekjukjeon-dacro, Giheung-gu, Yongin-si, Gyeonggi-do 446-916, Republic of Korea, for good and valuable consideration, have assigned and do hereby assign to CHONG KUN DANG PHARMACEUTICAL CORP. (hereinafter Assignee), a corporation organized under the laws of the Republic of Korea, having a principal business address of 8, Chungjeong-ro, Seodaemun-gu, Seoul 120-756, Republic of Korea, its successors, assigns and legal representatives, the entire right, title and interest in and to the subject matter disclosed in U.S. National Phase Patent Application Serial No. 14/440,060 entitled:

SUSTAINED-RELEASE LIPID PRE-CONCENTRATE OF GNRH  
ANALOGUES AND PHARMACEUTICAL COMPOSITION  
COMPRISING THE SAME

which was filed on April 30, 2015, and in and to all Convention and Treaty rights of all kinds, in all countries throughout the world, for all such subject matter, including the right to claim for any such applications any priority rights to which such applications are entitled under international conventions, treaties or otherwise and, in and to, all Letters Patent to be obtained for said subject matter by the above application or any continuation, division, continuation-in-part, extension, conversion to 35 USC 111(b) or substitute thereof, and any reissue, reexamination or extension of said Letters Patent.

ASSIGNMENT  
Sang Phil YOON *et al.*

I agree to do all acts and sign all documents necessary to secure, defend and maintain all said Letters Patent and rights, including any continuations, divisionals, reissues, renewals and extensions, and request issuance of all said Letters Patent to the above Assignee in accordance with this assignment.

ASSIGNOR:

DATE: 2015.08.13

  
\_\_\_\_\_  
Jin Young KO

WITNESSED:


DATE: August 13, 2015

  
\_\_\_\_\_  
[SIGNATURE OF WITNESS]

Ye Jin KWON  
\_\_\_\_\_  
[PRINTED NAME OF WITNESS]

WITNESSED:

DATE: August 13, 2015

  
\_\_\_\_\_  
[SIGNATURE OF WITNESS]

Jae Ock CHO  
\_\_\_\_\_  
[PRINTED NAME OF WITNESS]

ASSIGNMENT

I, So Hyun PARK (hereinafter Assignor), a citizen of the Republic of Korea, having a mailing address of 315-20, Dongbaekjukjeon-daero, Giheung-gu, Yongin-si, Gyeonggi-do 446-916, Republic of Korea, for good and valuable consideration, have assigned and do hereby assign to CHONG KUN DANG PHARMACEUTICAL CORP. (hereinafter Assignee), a corporation organized under the laws of the Republic of Korea, having a principal business address of 8, Chungjeong-ro, Seodaemun-gu, Seoul 120-756, Republic of Korea, its successors, assigns and legal representatives, the entire right, title and interest in and to the subject matter disclosed in U.S. National Phase Patent Application Serial No. 14/440,060 entitled:

SUSTAINED-RELEASE LIPID PRE-CONCENTRATE OF GNRH  
ANALOGUES AND PHARMACEUTICAL COMPOSITION  
COMPRISING THE SAME

which was filed on April 30, 2015, and in and to all Convention and Treaty rights of all kinds, in all countries throughout the world, for all such subject matter, including the right to claim for any such applications any priority rights to which such applications are entitled under international conventions, treaties or otherwise and, in and to, all Letters Patent to be obtained for said subject matter by the above application or any continuation, division, continuation-in-part, extension, conversion to 35 USC 111(b) or substitute thereof, and any reissue, reexamination or extension of said Letters Patent.

**ASSIGNMENT**  
Sang Phil YOON *et al.*

I agree to do all acts and sign all documents necessary to secure, defend and maintain all said Letters Patent and rights, including any continuations, divisionals, reissues, renewals and extensions, and request issuance of all said Letters Patent to the above Assignee in accordance with this assignment.

ASSIGNOR:

DATE: 2015. 8. 13

  
\_\_\_\_\_  
So Hyun PARK

WITNESSED:


DATE: August 13, 2015

  
\_\_\_\_\_  
[SIGNATURE OF WITNESS]

Ye Jin KWON  
\_\_\_\_\_  
[PRINTED NAME OF WITNESS]

WITNESSED:

DATE: August 13, 2015

  
\_\_\_\_\_  
[SIGNATURE OF WITNESS]

Jae Ock CHO  
\_\_\_\_\_  
[PRINTED NAME OF WITNESS]



ASSIGNMENT

I, **Sung Bum JUNG** (hereinafter **Assignor**), a citizen of the Republic of Korea, having a mailing address of 315-20, Dongbaekjukjeon-daero, Giheung-gu, Yongin-si, Gyeonggi-do 446-916, Republic of Korea, for good and valuable consideration, have assigned and do hereby assign to **CHONG KUN DANG PHARMACEUTICAL CORP.** (hereinafter **Assignee**), a corporation organized under the laws of the Republic of Korea, having a principal business address of 8, Chungjeong-ro, Seodaemun-gu, Seoul 120-756, Republic of Korea, its successors, assigns and legal representatives, the entire right, title and interest in and to the subject matter disclosed in U.S. National Phase Patent Application Serial No. 14/440,060 entitled:

**SUSTAINED-RELEASE LIPID PRE-CONCENTRATE OF GNRH  
ANALOGUES AND PHARMACEUTICAL COMPOSITION  
COMPRISING THE SAME**

which was filed on April 30, 2015, and in and to all Convention and Treaty rights of all kinds, in all countries throughout the world, for all such subject matter, including the right to claim for any such applications any priority rights to which such applications are entitled under international conventions, treaties or otherwise and, in and to, all Letters Patent to be obtained for said subject matter by the above application or any continuation, division, continuation-in-part, extension, conversion to 35 USC 111(b) or substitute thereof, and any reissue, reexamination or extension of said Letters Patent.

ASSIGNMENT  
Sang Phil YOON *et al.*

I agree to do all acts and sign all documents necessary to secure, defend and maintain all said Letters Patent and rights, including any continuations, divisionals, reissues, renewals and extensions, and request issuance of all said Letters Patent to the above Assignee in accordance with this assignment.

ASSIGNOR:

DATE: 2015. 8. 13

  
\_\_\_\_\_  
Sung Bum JUNG

WITNESSED:


DATE: August 13, 2015

  
\_\_\_\_\_  
[SIGNATURE OF WITNESS]

Ye Jin KWON  
\_\_\_\_\_  
[PRINTED NAME OF WITNESS]

WITNESSED:

DATE: August 13, 2015

  
\_\_\_\_\_  
[SIGNATURE OF WITNESS]

Jae Ock CHO  
\_\_\_\_\_  
[PRINTED NAME OF WITNESS]

ASSIGNMENT

I, Sung Won AN (hereinafter Assignor), a citizen of the Republic of Korea, having a mailing address of 315-20, Dongbaekjukjeon-daero, Giheung-gu, Yongin-si, Gyeonggi-do 446-916, Republic of Korea, for good and valuable consideration, have assigned and do hereby assign to CHONG KUN DANG PHARMACEUTICAL CORP. (hereinafter Assignee), a corporation organized under the laws of the Republic of Korea, having a principal business address of 8, Chungjeong-ro, Seodaemun-gu, Seoul 120-756, Republic of Korea, its successors, assigns and legal representatives, the entire right, title and interest in and to the subject matter disclosed in U.S. National Phase Patent Application Serial No. 14/440.060 entitled:

SUSTAINED-RELEASE LIPID PRE-CONCENTRATE OF GNRH  
ANALOGUES AND PHARMACEUTICAL COMPOSITION  
COMPRISING THE SAME


which was filed on April 30, 2015, and in and to all Convention and Treaty rights of all kinds, in all countries throughout the world, for all such subject matter, including the right to claim for any such applications any priority rights to which such applications are entitled under international conventions, treaties or otherwise and, in and to, all Letters Patent to be obtained for said subject matter by the above application or any continuation, division, continuation-in-part, extension, conversion to 35 USC 111(b) or substitute thereof, and any reissue, reexamination or extension of said Letters Patent.

ASSIGNMENT  
Sang Phil YOON *et al.*

I agree to do all acts and sign all documents necessary to secure, defend and maintain all said Letters Patent and rights, including any continuations, divisionals, reissues, renewals and extensions, and request issuance of all said Letters Patent to the above Assignee in accordance with this assignment.


ASSIGNOR:

DATE: 2015.8.13

  
\_\_\_\_\_  
Sung Won AN

WITNESSED:


DATE: August 13, 2015

  
\_\_\_\_\_  
[SIGNATURE OF WITNESS]

Ye Jin KWON  
\_\_\_\_\_  
[PRINTED NAME OF WITNESS]

WITNESSED:

DATE: August 13, 2015

  
\_\_\_\_\_  
[SIGNATURE OF WITNESS]

Jae Ock CHO  
\_\_\_\_\_  
[PRINTED NAME OF WITNESS]

ASSIGNMENT

I, Min Hyo KI (hereinafter Assignor), a citizen of the Republic of Korea, having a mailing address of 315-20, Dongbaekjukjeon-daero, Giheung-gu, Yongin-si, Gyeonggi-do 446-916, Republic of Korea, for good and valuable consideration, have assigned and do hereby assign to **CHONG KUN DANG PHARMACEUTICAL CORP.** (hereinafter Assignee), a corporation organized under the laws of the Republic of Korea, having a principal business address of 8, Chungjeong-ro, Seodaemun-gu, Seoul 120-756, Republic of Korea, its successors, assigns and legal representatives, the entire right, title and interest in and to the subject matter disclosed in U.S. National Phase Patent Application Serial No. 14/440,060 entitled:

**SUSTAINED-RELEASE LIPID PRE-CONCENTRATE OF GNRH  
ANALOGUES AND PHARMACEUTICAL COMPOSITION  
COMPRISING THE SAME**

which was filed on April 30, 2015, and in and to all Convention and Treaty rights of all kinds, in all countries throughout the world, for all such subject matter, including the right to claim for any such applications any priority rights to which such applications are entitled under international conventions, treaties or otherwise and, in and to, all Letters Patent to be obtained for said subject matter by the above application or any continuation, division, continuation-in-part, extension, conversion to 35 USC 111(b) or substitute thereof, and any reissue, reexamination or extension of said Letters Patent.

ASSIGNMENT  
Sang Phil YOON *et al.*

I agree to do all acts and sign all documents necessary to secure, defend and maintain all said Letters Patent and rights, including any continuations, divisionals, reissues, renewals and extensions, and request issuance of all said Letters Patent to the above Assignee in accordance with this assignment.

ASSIGNOR:


DATE: 2015. 8. 13



\_\_\_\_\_  
Min Hyo KI

WITNESSED:

DATE: August 13, 2015

  
\_\_\_\_\_  
[SIGNATURE OF WITNESS]

Ye Jin KWON

\_\_\_\_\_  
[PRINTED NAME OF WITNESS]

WITNESSED:

DATE: August 13, 2015

  
\_\_\_\_\_  
[SIGNATURE OF WITNESS]

Jae Ock CHO

\_\_\_\_\_  
[PRINTED NAME OF WITNESS]